- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
PACS firms can't forget workstations
PACS firms can't forget workstationsMuch has been accomplished in the last few years to facilitate radiologist acceptance of soft-copy reading and PACS technology, but clearly work still needs to be done.In a talk at the Diagnostic
PACS firms can't forget workstations
Much has been accomplished in the last few years to facilitate radiologist acceptance of soft-copy reading and PACS technology, but clearly work still needs to be done.
In a talk at the Diagnostic Imaging Healthcare Conference 1998: How to Buy, Use and Succeed with PACS, University of Pittsburgh Medical Center director of radiology informatics Dr. Paul Chang discussed the shortcomings of today's PACS workstations.
His comments were damning. Although he conceded that workstations have improved over the last two years, Chang believes they still have a long way to go.
In addition to his concern with the expensive "boxes" that can't do much besides view images, Chang points to the graphical user interface as a particular problem. Workstation interfaces are still much too busy, cumbersome, and full of distractions, he said. Soft-copy reading is hard enough without having to deal with a complicated, icon-rich interface.
The concept of user work flow has been only partially realized, Chang said. Scalability within the enterprise is difficult, and work flow and work list management implementations are still primitive. He would also like to see HIS/RIS interfaces enhanced.
Unfortunately, Chang's comments are right on the mark. PACS vendors would be wise to heed them. Although IS departments exert a growing influence in the PACS purchasing process, radiology departments are still key participants in the process. Ignoring the wishes of radiologists would be a big mistake.
-Erik L. Ridley, Editor
- Search again
- Homepage
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
